Barclays PLC Biocryst Pharmaceuticals Inc Transaction History

Barclays PLC

$327 Billion
Q2 2024

A detailed history of Barclays PLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Barclays PLC holds 226,586 shares of BCRX stock, worth $1.74 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

226,586

Previous 276,258 17.98%

Holding current value

$1.74 Million

Previous $1.4 Million 0.21%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.13 - $6.79 $205,145 - $337,272	-49,672 Reduced 17.98%	226,586 $1.4 Million
Q1 2024 May 15, 2024	SELL	$4.89 - $7.65 $2.09 Million - $3.28 Million	-428,271 Reduced 60.79%	276,258 $1.4 Million
Q4 2023 Feb 15, 2024	BUY	$4.98 - $6.77 $782,860 - $1.06 Million	157,201 Added 28.72%	704,529 $4.22 Million
Q3 2023 Nov 07, 2023	SELL	$6.71 - $7.92 $16,177 - $19,095	-2,411 Reduced 0.44%	547,328 $3.88 Million
Q2 2023 Aug 03, 2023	SELL	$6.96 - $8.81 $1.07 Million - $1.35 Million	-153,434 Reduced 21.82%	549,739 $3.87 Million
Q1 2023 May 04, 2023	BUY	$7.94 - $11.84 $1.74 Million - $2.59 Million	218,681 Added 45.14%	703,173 $5.86 Million
Q4 2022 Feb 13, 2023	BUY	$10.5 - $14.2 $766,248 - $1.04 Million	72,976 Added 17.73%	484,492 $5.56 Million
Q3 2022 Nov 03, 2022	BUY	$10.79 - $14.81 $3.5 Million - $4.81 Million	324,633 Added 373.64%	411,516 $5.18 Million
Q2 2022 Aug 12, 2022	SELL	$7.89 - $17.88 $279,653 - $633,738	-35,444 Reduced 28.97%	86,883 $918,000
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $1.11 Million - $1.9 Million	-96,205 Reduced 44.02%	122,327 $1.99 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $1.56 Million - $2.16 Million	139,616 Added 176.92%	218,532 $3.03 Million
Q3 2021 Nov 09, 2021	SELL	$14.21 - $17.65 $46,225 - $57,415	-3,253 Reduced 3.96%	78,916 $1.13 Million
Q2 2021 Aug 13, 2021	SELL	$9.5 - $17.24 $1.45 Million - $2.64 Million	-153,124 Reduced 65.08%	82,169 $1.3 Million
Q1 2021 May 13, 2021	BUY	$7.37 - $13.61 $1.01 Million - $1.87 Million	137,263 Added 140.02%	235,293 $2.39 Million
Q4 2020 Feb 11, 2021	SELL	$3.37 - $8.61 $639,204 - $1.63 Million	-189,675 Reduced 65.93%	98,030 $730,000
Q3 2020 Nov 12, 2020	SELL	$3.43 - $5.53 $295,000 - $475,613	-86,006 Reduced 23.01%	287,705 $987,000
Q2 2020 Aug 12, 2020	SELL	$1.9 - $5.61 $1.47 Million - $4.35 Million	-775,135 Reduced 67.47%	373,711 $1.78 Million
Q1 2020 May 13, 2020	BUY	$1.6 - $4.11 $1.52 Million - $3.9 Million	949,442 Added 476.14%	1,148,846 $2.3 Million
Q4 2019 Feb 10, 2020	SELL	$1.59 - $3.45 $53,745 - $116,616	-33,802 Reduced 14.49%	199,404 $688,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $319,077 - $476,063	-127,631 Reduced 35.37%	233,206 $669,000
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $742,084 - $2.33 Million	255,012 Added 240.98%	360,837 $1.37 Million
Q1 2019 May 15, 2019	BUY	$7.38 - $9.72 $478,895 - $630,740	64,891 Added 158.53%	105,825 $861,000
Q4 2018 Feb 14, 2019	SELL	$6.51 - $9.6 $27,433 - $40,454	-4,214 Reduced 9.33%	40,934 $330,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $187,956 - $272,059	34,050 Added 306.81%	45,148 $345,000
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $84,529 - $119,811	-18,376 Reduced 62.35%	11,098 $64,000
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $25,234 - $33,761	5,801 Added 24.5%	29,474 $140,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $36,516 - $46,786	8,778 Added 58.93%	23,673 $116,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $61,069 - $88,923	14,895	14,895 $78,000

Others Institutions Holding BCRX

# of Institutions

260

Shares Held

173M

Call Options Held

397K

Put Options Held

444K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.43B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account